Compounds > n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
Page last updated: 2024-09-03

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and baricitinib

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with baricitinib in 1 studies

Compound Research Comparison

Studies
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)		Trials
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)		Recent Studies (post-2010)
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)		Studies
(baricitinib)		Trials
(baricitinib)		Recent Studies (post-2010) (baricitinib)
21455865395631

Protein Interaction Comparison

ProteinTaxonomyn(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50)baricitinib (IC50)
Cyclin-G-associated kinaseHomo sapiens (human)0.136
Tyrosine-protein kinase JAK2Homo sapiens (human)0.1233
Tyrosine-protein kinase JAK1Homo sapiens (human)0.0739
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)0.1565
Tyrosine-protein kinase JAK3Homo sapiens (human)0.4477
AP2-associated protein kinase 1Homo sapiens (human)0.017

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Warren, RB; Yiu, ZZ1

Reviews

1 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and baricitinib

ArticleYear
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    American journal of clinical dermatology, 2016, Volume: 17, Issue:3

    Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles

2016